Marine microorganisms have proved to be an important source of pharmacologically active metabolites, and a growing number of marine-derived fungi have been reported to produce metabolites with unique structures and interesting biological activities. 1, 2 The genus Aspergillus (Moniliaceae), with over 180 species, has attracted considerable attention as a rich source of alkaloids, terpenoids, xanthones, polyketides and etc, some of which showed antifungal, antibacterial, anti-HIV and cytotoxic activities. [3] [4] [5] In order to obtain new bioactive metabolites from marine fungi, we investigated on the marine fungal strain Aspergillus sydowii SCSIO 00305 isolated from a healthy tissue of Verrucella umbraculum. Bioassay-guided fractionation led to the isolation of a new indole diketopiperazine alkaloid, cyclotryprostatin E (1), together with nine known ones, [4-(2-methoxyphenyl)-1-piperazinyl][(1-methyl-1H-indol-3-yl)]-methanone (2), cyclotryprostatin B (3), 6 fumiquinazoline D (4), 7 fumitremorgin B (5), 8 fumiquinazoline C (6), 7 fumiquinazoline B (7), 7 fumiquinazoline A (8), 7 fumiquinazoline F (9), 7 fumiquinazoline G (10) 7 from a culture broth of the strain. The structures of compounds (1) and (2) were characterized by spectroscopic data interpretation. Compound (2) was a synthetical compound, however, no reference for it. The NMR data and biology source of (2) were reported for the first time. We present herein the fermentation, isolation, structure elucidation and cytotoxicity of compounds (1) and (2) .
Compound (1) (1) showed similarity to those of (3), 3 which suggested that (1) (1) was determined by the NOESY spectrum, the magnitude of 1 H-1 H COSY coupling constants, and comparison of the 13 C NMR data of (1) with those of (3). The observed NOE correlations between H-3 and H 3 -24/H 2À 21, between H 3 -24 and H 2 -21, and between H-6 and H-7a/H-8a, together with nearly identical carbon chemical shift of C-12 (d C 87.3 in (1) and 84.7 in (3)) and C-13 (d C 77.6 in (1) and 76.8 in (3)), indicated that (1) had the same relative configuration as 3.
Compound (2) to C-3/C-7/C-9, from H-2 to C-3/C-4/C-9, and from H-8 to C-4/C-6 suggested the existence of one indolyl group, one piperazinyl group, and one 1,2-disubstituted phenyl group. One methyl group and one methoxyl group were deduced to be located at N-1 and C-19, respectively, from the observation of HMBC correlations from d H 3.84 (6H, s) to C-2/C-9/C-19. This information coupled with the key HMBC correlations from H-2, H-13 and H-17 to C-11 and from H-14 and H-16 to C-18 enabled us to establish the structure of (2) as shown in Figure 2 . We proposal that chorismate acid may be a biogenetic precursor for (2) .
Compounds (1) and (2) were screened for their cytotoxicity against A549 (lung cancer cell line), A375 (human melanoma cell line) and Hela (Human cervical carcinoma cell) cell lines, using the MTT method with cis-platin as positive control. Compound (2) showed significant cytotoxicity against A375 cell lines with IC 50 (half maximal inhibitory concentration) value of 5.7 mM. Compound (1) had no obvious cytotoxicity towards the above mentioned three cell lines.
EXPERIMENTAL PROCEDURE Taxonomy
The fungus A. sydowii SCSIO 00305 was isolated from a healthy tissue of V. umbraculum collected from Sanya, Hainan Province, China, and was identified by Dr Xiaoyong Zhang, and a voucher specimen (A. sydowii SCSIO 00305) has been deposited in the RNAM Center for Marine Microbiology, South China Sea Institute of Oceanology, Chinese Academy of Sciences.
Fermentation, isolation and identification of compounds
The fungus strain A. sydowii SCSIO 00305 was cultivated in 500 ml Erlenmeyer flasks containing 100 ml of the production medium composed of glucose 1%, maltose 2%, mannitol 2%, yeast extract 0.3%, monosodium glutamate 1%, MgSO 4 Á7H 2 O 0.03%, KH 2 PO 4 0.05% and sea water 5 l (pH 7.2 before sterilization), and cultured without shaking at 28 1C for 20 days. The EtOAc extract of mycelia (800 mg) was chromatographed on RP-C 18 column using gradient elution from 5% MeOH/H 2 O to100% MeOH, to give four fractions. Fraction A (MeOH/H 2 O, 35% v/v elution, 100 mg) was further purified by semi-preparative reversed-phase HPLC (MeOH/H 2 O 45 % v/v, 3 ml/min, detector 230 nm) to yield (5) (t R ¼23.1 min), (6) (t R ¼28.0 min), (8) (t R ¼32.5 min). Fraction B (MeOH/H 2 O, 55% v/v elution, 120 mg) was further purified by semi-preparative reversed-phase HPLC (MeOH/H 2 O 50% v/v, 3 ml/min, detector 230 nm) to yield (1) (t R ¼16.6 min), (4) (t R ¼18.9 min), (9) (t R ¼22.1 min) and (10) (t R ¼23.8 min). Fraction C (MeOH/H 2 O, 75% v/v elution, 250 mg) was further purified by reversed-phase HPLC (60%CH 3 CN/ H 2 O, 3 ml/min, detector 254 nm) to yield (2) (t R ¼12.8 min), (3) (t R ¼15.2 min) and (7) 
